Lp(a)HORIZON and ZEUS hit their biomarker targets but not MACE. Stephen Greene, MD, and Muthiah Vaduganathan, MD, MPH, unpack both at AHA 2026.
|Articles|June 22, 2011
Hyponatremia: A Serious Sodium Deficiency
Author(s)Healthy Body Healthy Mind
Dr. Verbalis, Dr. Green, and Dr. Miller explain the effects of hyponatremia and Marilyn Getty describes her experience with the condition.
Advertisement
Dr. Joseph Verbalis, Dr. Robert Green, and Dr. Myron Miller discuss hyponatremia and its effects. Marilyn Getty describes how the condition has personally impacted her life experiences.
Advertisement
Related to this article
Stay updated with the latest healthcare breakthroughs, including 96-week durability data for GSK’s bepirovirsen in hepatitis B, and more.
The FDA approved asundexian with antiplatelet therapy after noncardioembolic ischemic stroke or high-risk TIA, based on OCEANIC-STROKE data.
Kausik Ray, MD, MBChB, MPhil, discusses Lp(a)HORIZON, remnant cholesterol targets, enlicitide, and the lipid outcome trials to watch in 2027.
In 757 adults with severe hypertriglyceridemia, plozasiran cut acute pancreatitis events by 78% overall and 91% in those with recent prior pancreatitis.
With LDL-C target-guided titration, starting statin plus ezetimibe vs a statin alone yielded similar 3-year events in ASCVD.
Stopping statins was noninferior at 2 years in adults 70 and older without CVD, but events were higher over full follow-up (12.7% vs 9.2%).
Asundexian lowered ischemic stroke without more major bleeding across low, intermediate, and high Framingham risk groups (all P interaction > .25).
Advertisement
Advertisement
Trending on HCPLive
1
Q&A: Mucus Plugging, Multimorbidity, and GOLD 2027, With Gerard Criner, MD
2
IL-33 Biologics and the 2027 GOLD Report, With Dave Singh, MD
3
Enlicitide Lowers LDL-C Consistently Across PREVENT CVD Risk Categories
4
Omalizumab Biosimilar CT-P39: Quality of Life Gains Precede CSU Control
5